An empirical analysis of overall survival in drug approvals by the US FDA (2006–2023)
Abstract Background The US Food and Drug Administration (FDA) has expanded the use of surrogate markers in drugs approved for oncology/hematology indications. This has likely resulted in a greater number of approvals and possibly drugs coming to market faster, but it is unknown whether these drugs a...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Wiley
2024-04-01
|
| سلاسل: | Cancer Medicine |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1002/cam4.7190 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|